Jihane N. Benhammou, MD, PhD

Jihane N. Benhammou, MD, PhD

Assistant Professor of Medicine, Department Medicine/Digestive Diseases

Languages

English

Education

Fellowships

Gastroenterology, University of California, Los Angeles, 2018
Transplant Hepatology, University of California, Los Angeles, 2018

Internship

Internal Medicine, UCLA School of Medicine, 2012

Degrees

PhD, University of California, Los Angeles, 2019
MD, University of California, Los Angeles, 2011
BS, University of Texas, Austin, 2005

Residency

Internal Medicine, University of California, Los Angeles, 2014

Board Certifications

Transplant Hepatology, American Board of Internal Medicine, 2020
Gastroenterology, American Board of Internal Medicine, 2018
Internal Medicine, American Board of Internal Medicine, 2014

Contact Information

Scientific Interests

Dr. Benhammou is a transplant hepatologiost and physician-scientist interested in understanding the transition from non-alcoholic fatty liver to hepatocellular carcinoma with the goal to identify new screening tools and chemoprevention methods using lipid modulating agents, including statins.

Highlighted Publications

Benhammou JN*, Rich NE*, Cholankeril G, Zhang P, Zeng W, Rao S on behalf of TLC-ECW working group: Li W, Wu X, Feng S, Fujiwara N, Meng X, Zhu S, Zaidi S, Tayob N. DETECT: Development of Technologies for Early HCC detection. Gastroenterology (in press)

Rao S, Ohshiro K, Zaidi S, Wang Z, Shetty K, Hassan MI, Mohammad T, Latham PS, Nguyen BN, Wong L, Yu H, Jogunoori W, Vacca M, Guienigault G, Allison EA, Vital-Puig A, Alvarez M, Pajukanta P, Benhammou JN, Pisegna JR, Mirshar L. Beta spectrim (SPTBN1) deficiency protects mice from highfat diet-induced liver disease and cancer development. Sci Transl Med, 2021. PMID: 34910547.

Benhammou JN, Lin J, Aby ES, Markovic D, Raman S, Lu D, Tong MJ. Characterization of hepatocellular carcinoma growth rates in non-alcoholic fatty liver disease. Hepatoma Res, 2021. PMID: 34966854.

Benhammou JN, Moon AM, Pisegna JR, Su F, Vutien P, Moylan CA, Ioannou GN. Nonalcoholic fatty liver disease metabolic factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C. Dig Dis and Sci, 2020, PMID: 32654086.

Aby ES, Winters AC, Lin Jonathan, Bui A, Kawamoto J, Goetz MB, Bhattacharya D, Pisegna JR, May F, Patel AA, Benhammou JN. A telephone and mail outreach program successfully increases uptake of hepatocellular carcinoma. Hepatol Commun 4 (6): 825-833, 2020. PMID: 32490319 PMCID: PMC7262281

In the News

View more articles